You are here

  • Home
  • Archive
  • Volume 65, Issue 11
  • Refractory auto-inflammatory syndrome associated with digenic transmission of low-penetrance tumour necrosis factor receptor-associated periodic syndrome and cryopyrin-associated periodic syndrome mutations

Article Text

Article menu
Download PDFPDF
Letters
Refractory auto-inflammatory syndrome associated with digenic transmission of low-penetrance tumour necrosis factor receptor-associated periodic syndrome and cryopyrin-associated periodic syndrome mutations
  1. I Touitou1,
  2. C Perez2,
  3. B Dumont1,
  4. L Federici1,
  5. C Jorgensen2
  1. 1Unité médicale des maladies autoinflammatories, Laboratoire de génétique, Hôpital A de Villeneuve, CHU de Montpellier, Montpellier, France
  2. 2Unité clinique d’immunorhumatologie, Hôpital Lapeyronie, CHU de Montpellier, Montpellier, France
  1. Correspondence to:
    I Touitou
    Unité médicale des molodies autoinflammatories, Laboratoire de génétique, Hôpital A de Villeneuve, CHU de Montpellier, 34295 Montpellier, Cedex 5, France;isabelle.touitou{at}igh.cnrs.fr

https://doi.org/10.1136/ard.2006.054312

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Two dominant periodic fevers, tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) and cryopyrin-associated periodic syndrome (CAPS), are prominent auto-inflammatory disorders. Mutations in the 55 kDa TNF receptor superfamily 1A gene (TNFRSF1A) and in the cold-induced auto-inflammatory syndrome 1 gene (CIAS1) were recently associated with TRAPS1 and CAPS,2 respectively. Following publications describing the efficacy of etanercept (enbrel), a recombinant human TNF receptor 1B fusion protein in patients with TRAPS3 and anakinra (kineret), a recombinant human interleukin-1 (IL1)-receptor antagonist, in patients with CAPS,4 targeted biotherapies have been repeatedly and successfully given for these two conditions.

    Our proband (fig 1⇓) is a 36-year-old French woman who presented with rashes of urticaria and oedema precipitated by exposure to heat and water. These rashes, lasting …

    View Full Text

    Footnotes

    • See linked article, p 1427

    • Competing interests: None declared.

    Linked Articles